Cargando…

Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention

Radiation is the most potent mode of cancer therapy; however, resistance to radiation therapy results in tumor relapse and subsequent fatality. The cancer stem cell (CSC), which has better DNA repair capability, has been shown to contribute to tumor resistance and is an important target for treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pranatharthi, Annapurna, Ross, Cecil, Srivastava, Sweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002480/
https://www.ncbi.nlm.nih.gov/pubmed/27597870
http://dx.doi.org/10.1155/2016/5785786
_version_ 1782450575637479424
author Pranatharthi, Annapurna
Ross, Cecil
Srivastava, Sweta
author_facet Pranatharthi, Annapurna
Ross, Cecil
Srivastava, Sweta
author_sort Pranatharthi, Annapurna
collection PubMed
description Radiation is the most potent mode of cancer therapy; however, resistance to radiation therapy results in tumor relapse and subsequent fatality. The cancer stem cell (CSC), which has better DNA repair capability, has been shown to contribute to tumor resistance and is an important target for treatment. Signaling molecules such as Notch, Wnt, and DNA repair pathways regulate molecular mechanisms in CSCs; however, none of them have been translated into therapeutic targets. The RhoGTPases and their effector ROCK-signaling pathway, though important for tumor progression, have not been well studied in the context of radioresistance. There are reports that implicate RhoA in radioresistance. ROCK2 has also been shown to interact with BRCA2 in the regulation of cell division. Incidentally, statins (drug for cardiovascular ailment) are functional inhibitors of RhoGTPases. Studies suggest that patients on statins have a better prognosis in cancers. Data from our lab suggest that ROCK signaling regulates radioresistance in cervical cancer cells. Collectively, these findings suggest that Rho/ROCK signaling may be important for radiation resistance. In this review, we enumerate the role of Rho/ROCK signaling in stemness and radioresistance and highlight the need to explore these molecules for a better understanding of radioresistance and development of therapeutics.
format Online
Article
Text
id pubmed-5002480
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50024802016-09-05 Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention Pranatharthi, Annapurna Ross, Cecil Srivastava, Sweta Stem Cells Int Review Article Radiation is the most potent mode of cancer therapy; however, resistance to radiation therapy results in tumor relapse and subsequent fatality. The cancer stem cell (CSC), which has better DNA repair capability, has been shown to contribute to tumor resistance and is an important target for treatment. Signaling molecules such as Notch, Wnt, and DNA repair pathways regulate molecular mechanisms in CSCs; however, none of them have been translated into therapeutic targets. The RhoGTPases and their effector ROCK-signaling pathway, though important for tumor progression, have not been well studied in the context of radioresistance. There are reports that implicate RhoA in radioresistance. ROCK2 has also been shown to interact with BRCA2 in the regulation of cell division. Incidentally, statins (drug for cardiovascular ailment) are functional inhibitors of RhoGTPases. Studies suggest that patients on statins have a better prognosis in cancers. Data from our lab suggest that ROCK signaling regulates radioresistance in cervical cancer cells. Collectively, these findings suggest that Rho/ROCK signaling may be important for radiation resistance. In this review, we enumerate the role of Rho/ROCK signaling in stemness and radioresistance and highlight the need to explore these molecules for a better understanding of radioresistance and development of therapeutics. Hindawi Publishing Corporation 2016 2016-08-15 /pmc/articles/PMC5002480/ /pubmed/27597870 http://dx.doi.org/10.1155/2016/5785786 Text en Copyright © 2016 Annapurna Pranatharthi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pranatharthi, Annapurna
Ross, Cecil
Srivastava, Sweta
Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
title Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
title_full Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
title_fullStr Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
title_full_unstemmed Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
title_short Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
title_sort cancer stem cells and radioresistance: rho/rock pathway plea attention
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002480/
https://www.ncbi.nlm.nih.gov/pubmed/27597870
http://dx.doi.org/10.1155/2016/5785786
work_keys_str_mv AT pranatharthiannapurna cancerstemcellsandradioresistancerhorockpathwaypleaattention
AT rosscecil cancerstemcellsandradioresistancerhorockpathwaypleaattention
AT srivastavasweta cancerstemcellsandradioresistancerhorockpathwaypleaattention